Business Wire

Boehringer Ingelheim Phase III study now enrolling patients with progressive fibrosing lung diseases


Boehringer Ingelheim today announced that the first patient has been enrolled in the PF-ILD (progressive fibrosing interstital lung disease) trial. This study investigates the efficacy and safety of nintedanib in a range of progressive fibrosing lung conditions other than idiopathic pulmonary fibrosis (IPF).1

There are over 200 conditions that affect the tissue and space around the air sacs of the lungs (interstitium). These conditions are called interstitial lung diseases or ILDs.2 Based on clinical obervations there are groups of patients with ILD who independent from the classification of the ILD, exhibit a progressive fibrosing behaviour.3-6 The proposed terminology for describing this group of patients is PF-ILD. In these patients the disease appears to follow a course similar to IPF with worsening of respiratory symptoms, lung function, quality of life and ability to perform daily activites, as well as early mortality despite treatment.3-6

“This trial enrolls patients who have lung fibrosis of at least 10% by chest imaging that is getting worse by symptoms, physiology or imaging despite treatment,” said Kevin Flaherty, Coordinating Principal Investigator of the PF-ILD trial. “This trial is an innovative way to study a potential treatment for patients with progressive fibrosing lung diseases and is an important step in exploring the way fibrosis of the lung is treated and whether nintedanib could be an effective therapy.”

Nintedanib*, which is marketed as OFEV®, is approved for a rare lung disease called IPF, in which it has been shown to slow disease progression as measured by annual rate of decline in lung function.7-10 Building on the positive real-world clinical experience in IPF, the Phase III trial is now exploring whether nintedanib can effectively target the scarring in the lungs of patients suffering from other progressive fibrosing-ILDs.

“Boehringer Ingelheim is dedicated to advancing the understanding of fibrosing lung diseases where no or limited treatments exist,” said Dr Christopher Corsico, Chief Medical Officer Boehringer Ingelheim. “Our innovative PF-ILD trial is designed to include patients with fibrosing lung diseases who would not otherwise be eligible to participate in a clinical trial. This demonstrates the commitment of Boehringer Ingelheim to transform fibrosing interstitial lung diseases from fatal diseases to chronic, treatable ones.”

*Nintedanib is currently not approved for use in PF-ILD and its safety and efficacy has not yet been fully established.

~ ENDS ~

Please click on the link below for ‘Notes to Editors’ and ‘References’:

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business.

Contact information

Boehringer Ingelheim
Corporate Communications
Media + PR
Dr. Kristin Jakobs
Phone: +49 6132 – 77 144553
Fax: +49 6132 – 77 6601

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Advantis Medical Imaging Receives CE Mark for Brainance® MD, its Cloud-Based Neuroimaging Software.20.3.2018 11:00Pressemelding

Advantis Medical Imaging announces that it received CE Mark approval for Brainance ® MD, its Cloud-Based Neuroimaging software. This market approval allows Brainance ® MD to be used as part of the clinical workflow for the advanced processing of Brain MR images. This press release features multimedia. View the full release here: “We feel really excited to make this announcement. This is a significant milestone for our company and the fact that Brainance ® MD can now be integrated in the clinical processing workflow fulfills one of Advantis principal goals: to make state-of-the-art processing methodologies available for every doctor, anywhere, anytime. ” said Zoi Giavri, CEO and co-founder of Advantis Medical Imaging. “This CE Mark approval confirms our capacity for innovation and justifies the entire team’s devotion and effort on striving for increased quality and performance, while bringing added value to the daily clinical pra

Tan Delta: Not All Condition Based Monitoring is the Same.20.3.2018 10:35Pressemelding

Condition based monitoring (CBM) and maintenance programmes typically include many interrelated technologies. CBM provides an assessment of equipment condition, based on collecting and interpreting data with a view to providing maintenance at the optimum point. This allows a company to make cost-effective and logical maintenance decisions, reducing scheduled costs and reducing in-service fault repair costs, by eliminating run-to-failure and the associated consequences of unscheduled downtime. This press release features multimedia. View the full release here: Tan Delta: Not All Condition Based Monitoring is the Same. (Photo: Business Wire) Oil analysis is increasingly recognised as a critical element of condition based monitoring. Oil analysis provides important information about equipment wear-condition, as well as the condition of the oil itself. Keeping machinery operating at the optimal level involves measuring, monitoring a

Accudyne Industries Selects LTI as its IT Infrastructure & Security Management Partner20.3.2018 10:30Pressemelding

Larsen & Toubro Infotech Ltd. (NSE: LTI, BSE: 540005), a global technology consulting and digital solutions company, has been selected by Accudyne Industries, LLC (Accudyne Industries) as the transformation partner to provide IT Infrastructure & Security Management Services. Accudyne Industries is a leading global provider of precision engineered, process-critical and technologically advanced flow control systems and industrial compressors. Accudyne’s businesses support complex, large-scale installations within oil and gas, energy, petrochemical, chemical, industrial manufacturing, construction, mining, and water and wastewater treatment industries. Accudyne chose LTI as its consulting and IT services partner to enhance end-user experience while attaining flexibility and scalability across its business landscape. LTI will provide services leveraging an intelligent, global, managed services engagement model supported by a command and security operations center. Frank DeArmas, Chief Info

Favorable safety profile of Pradaxa® (dabigatran etexilate) confirmed in large prospective real-world analysis20.3.2018 10:09Pressemelding

New data from one of the largest prospective ongoing global studies examining the use of oral antithrombotics for stroke prevention in atrial fibrillation (AF) in clinical practice, GLORIATM-AF, were presented at the EHRA 2018, the annual congress of the European Heart Rhythm Association (EHRA).1,2 The registry examined two-year safety and effectiveness outcomes of nearly 5,000 AF patients treated with dabigatran (marketed as Pradaxa®). Results of the completed Phase II of GLORIATM-AF,1 presented during the ‘Late-breaking science – Registries’ session, showed low rates of major bleeding (0.97%) and stroke (0.65%). These findings confirm the sustained safety and effectiveness of dabigatran and are highly consistent with the long-term safety profile observed in other real-world evidence, as well as in randomised clinical trials. This press release features multimedia. View the full release here: “Long-term, ‘real-world’ data are i

IDEMIA: Easier Travel with the Biometric Innovations Presented at Passenger Terminal Expo (20–22 March 2018)20.3.2018 09:46Pressemelding

IDEMIA, the global leader in Augmented Identity, has announced his attendance to Passenger Terminal Expo (PTE) 2018, the world’s biggest aviation industry exhibition. Bringing together all industry stakeholders, including airlines, airport operators and public authorities, PTE begins today and will be held in Stockholm until March 22 nd . As passenger numbers in airports continue to soar1, the need to manage flows efficiently coupled with particularly rigorous screening procedures, is becoming more strategic than ever. With its innovative Augmented Identity, IDEMIA provides a smoother passenger experience based on identification whilst ensuring that security requirements are respected. In that context, IDEMIA today operates free-flow passenger solutions in several international airports through the world. For instance, Singapore Changi Airport, voted the world’s best airport for the fifth consecutive year, recently chose IDEMIA for the provision of biometric identification and authenti

ESSENZIALED Recessed & Linear Lamps Have Adopted Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs20.3.2018 08:07Pressemelding

Seoul Semiconductor, a global innovator of LED products and technology, announced that its SunLike Series natural spectrum LEDs, which implement light closest to the spectrum of natural sunlight, has been adopted for luminaires from ESSENZIALED, including the Spottone and Mood Series luminaires. This press release features multimedia. View the full release here: ESSENZIALED Mood-Round & Square spotlights with SunLike LEDs (Photo: Business Wire) Marino Bertazza, CEO and founder of ESSENZIALED, explained, “SunLike technology delivers a superior color rendering index, with a spectrum that closely matches that of natural sunlight. Our customers appreciate the quality of light and the visual comfort delivered by SunLike Series natural spectrum LEDs.” According to Caleb Won, executive VP of global marketing at Seoul Semiconductor, “ESSENZIALED’s choice of SunLike Series natural spectrum LEDs will achieve synergy effects and contribute